U.S. Companies Subjected to New Activist Campaigns Increased by 10.6% in 2022, According to Diligent
16.2.2023 17:00:00 EET | Business Wire | Press release
Last year, companies subjected to new activist campaigns increased by 10.6% in the U.S. and 6% globally in 2022, according to a new report released today by Diligent, the global leader in modern governance providing SaaS solutions across governance, risk, compliance, audit and ESG. The Shareholder Activism Annual Review 2023 report, produced by Insightia (a Diligent brand) shows that activism flourished in 2022 with the number of campaigns returning to pre-pandemic levels, spurred on by the introduction of the universal proxy.
The rising number of campaigns underscores the need for leaders to have a 360-view of data across their organization, strengthening their ability to identify which red flags to escalate to the board, monitor and mitigate evolving risks, and document compliance and risk management efforts in defensible, auditable detail.
“Amid heightened focus on a company’s bottom line, it is increasingly important for leaders to address and mitigate the ever-evolving risks of shareholder activism,” said Josh Black, editor-in-chief at Diligent. “Complete visibility into organizational data is the first step to building such a program and reducing vulnerability to investor, shareholder, and legal action.”
Among the report’s top findings:
The U.S. and Japan drove activity, with a focus on capital allocation, board changes, and ESG
- In the U.S., 511 companies faced activist demands, a 10.6% increase from 2021. This is in part due to the universal proxy rules, which have sent a jolt through the industry as advisers try to model how the greater choice available to investors will influence voting decisions.
- Japan proved especially attractive to activists, thanks to an increasing number of domestic investors looking to capitalize on undervalued companies. In 2022, 108 companies faced demands, almost double the 67 and 66 companies targeted throughout 2020 and 2021, respectively.
Investors’ expectations on executive compensation continue to increase
- Amid tightening markets and global interest rate rises, pay for performance compensation is becoming a regular part of investor engagements, with 114 companies facing remuneration demands globally throughout 2022, compared to 86 and 92 throughout 2020 and 2021, respectively.
- 1,397 Russell 3000 CEOs received pay increases of between 1-250% from FY2020 and FY2021, with average CEO pay exceeding $22.5 million. Pay revolts are also on the rise, with average support for S&P 500 advisory “say on pay” plans reaching an eight-year low of 87.5% in 2022.
ESG activism is facing a crisis of confidence
- Only 11.5% of environmental demands were at least partially successful in 2022, compared to 25.8% a year prior.
- With green stocks underperforming and oil and gas prices soaring, ESG campaigns that failed to make a compelling link between a company’s financial performance and ESG credentials were doomed to fail.
The Shareholder Activism Annual Review, produced in association with Olshan Frome Wolosky, Morrow Sodali, and Alliance Advisors, is Insightia’s flagship report for data on shareholder engagement, corporate governance, and compensation.
To download the full report click here, or to view our archive of publications, visit the resource center section on the Insightia website.
About the Report
Data from Insightia’s Activism, Shorts, Voting, and Vulnerability modules run from January 1 to December 31, 2022. Compensation data runs from June 1, 2021, to May 31, 2022. Further data is available on request. For more information, please email insightia.info@diligent.com.
About Insightia
Insightia, a Diligent brand since January 2022, is a leading SaaS provider of expert insights and intelligent analytics with a focus on shareholder activism, proxy voting and corporate governance. Through its web application, Insightia One, clients can access the most complete solution for listed company intelligence on the market, with broader and deeper insights than ever before.
About Diligent
Diligent is the global leader in modern governance, providing SaaS solutions across governance, risk, compliance, audit and ESG. Empowering more than 1 million users and 700,000 board members with a holistic view of their organization’s GRC practices so they can make better decisions, faster. No matter the challenge. Learn more at diligent.com.
Follow Diligent on LinkedIn, Twitter, and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230216005218/en/
Contact information
Julia Hanbury
Senior Marketing Communications Manager, Diligent
+1 778-822-6411
Jhanbury@diligent.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
